ForaCare Announces New Clinical Validations for Its Blood Glucose Monitors
ST. GALLEN, Switzerland, June 2, 2015 / ForaCare Suisse AG located in St. Gallen, Switzerland, announced today new clinical validations for its line of blood glucose monitors. The new validations continue the high level of quality its partners and end users have come to expect from ForaCare.

ForaCare’s blood glucose monitors meet the new ISO criteria of ± 15%.

We are proud to share the latest ISO 15197:2013 clinical validation study list. As ForaCare continues to provide excellence in clinical competency, our blood glucose monitoring systems continue higher accuracy in blood glucose measurement said Ty-Minh Tan, CEO of ForaCare Suisse AG.

FORA Diamond GD50 offer the highest clinical accuracy and system performance available, since it meets the recently released guidelines of the new ISO 15197:2013.

All ForaCare monitoring devices are validated as highly accurate in the industry and provide superior quality directly to consumers.  FORA Blood Glucose Monitors are validated according to ISO 15197:2013 requirements at an internationally renowned diabetes institute in Ulm, Germany.

ForaCare devices comply with new ISO standards and have completed third party validations.  To view validations for ForaCare’s devices, please visit:  http://www.foracare.ch/validations.html or see the graph below for device and numbers of validations for each model:

Fora Care provides FDA cleared and CE marked innovative health monitoring devices that provide simple connection to the FORA system. For more information, please visit http://www.foracare.ch/

About ForaCare Suisse AG: http://www.foracare.ch/


Elena Birrer
Email: elena.birrer@foracare.com
Website: http://www.foracare.ch

SOURCE ForaCare Suisse AG